Kamada (KMDA) said Tuesday that its operations and manufacturing in Israel are continuing, and global product availability remains unaffected by recent events in the Middle East.
The biopharmaceutical company said its shipments from Israel may be temporarily affected by the current closure of Israeli airspace but that its distribution centers outside Israel and international partners have sufficient level of products to meet client demands.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.